Skip to main content
Fig. 6 | BMC Complementary Medicine and Therapies

Fig. 6

From: Antidiabetic potential of Lysiphyllum strychnifolium (Craib) A. Schmitz compounds in human intestinal epithelial Caco-2 cells and molecular docking-based approaches

Fig. 6

The proposed mechanisms by which 3,5,7-trihydroxychromone-3-O-α-L-rhamnopyranoside (compound 1) and 3,5,7,3’,5’-pentahydroxy-flavanonol-3-O-𝛼-L-rhamnopyranoside (compound 2) inhibit glucose catalysis in enterocytes of the small intestine and their effect on the glucose transporter SGLT1, GLUT2, and GLUT5

Back to article page